Cocrystal Pharma (COCP) Non-Current Deferred Tax Liability (2010 - 2020)

Cocrystal Pharma has reported Non-Current Deferred Tax Liability for 11 years, with the latest figure at $2.2 million in Q4 2020.

• Quarterly Non-Current Deferred Tax Liability rose 24144.44% year-over-year to $2.2 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $2.2 million (up 24144.44% YoY) and the FY2020 annual result came in at $2.2 million, up 24144.44% from the prior year.
• Non-Current Deferred Tax Liability improved to $2.2 million in Q4 2020 per COCP's latest filing, from $9000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $49.9 million in Q1 2016 and troughed at $9000.0 in Q4 2019.
• A 5-year average of $18.3 million and a median of $12.9 million in 2018 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability tumbled 99.56% in 2019, then soared 24144.44% in 2020.
• Over 5 years, Non-Current Deferred Tax Liability stood at $1.4 million in 2016, then increased by 28.71% to $1.8 million in 2017, then rose by 13.08% to $2.0 million in 2018, then slumped by 99.56% to $9000.0 in 2019, then jumped by 24144.44% to $2.2 million in 2020.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.2 million, $9000.0, and $2.0 million for Q4 2020, Q4 2019, and Q4 2018 respectively.